| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Sangivamycin (NSC-65346) is a novel and potent antitumor antibiotic and antivirus antibiotic structurally similar to adenosine. It inhibits protein kinase C and the synthesis of both DNA and RNA.
| ln Vitro |
Antitumor effects Sanjivamycin (0.3 μM; 0-72 hours) shows almost maximal cell killing (for MCF7/ADR) or cell growth inhibition (for MCF7/WT) effects. Sangemycin has differential antitumor effects in drug-sensitive MCF7/wild-type (WT) tumor cells, leading to growth induction. Use of MCF7/doxorubicin (ADR) in drugs has differential antitumor effects in human breast cancer cells. Caspases in cells MCF7/ADR. Within 48 hours of Sangivamycin (0.3 μM) exposure, lamin A was found in significant levels, broken into 28 kDa pieces, in MCF7/ADR cells [2].
|
|---|---|
| References |
|
| Additional Infomation |
Sangivamycin is a nucleoside analogue that is adenosine in which the nitrogen at position 7 is replaced by a carbamoyl-substituted carbon. It is a potent inhibitor of protein kinase C. It has a role as a protein kinase inhibitor. It is functionally related to an adenosine.
Sangivamycin has been reported in Streptomyces and Streptomyces sparsogenes with data available. |
| Molecular Formula |
C12H15N5O5
|
|---|---|
| Molecular Weight |
309.28
|
| Exact Mass |
327.118
|
| CAS # |
18417-89-5
|
| PubChem CID |
14978
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
880.6ºC at 760 mmHg
|
| Flash Point |
486.4ºC
|
| Vapour Pressure |
3.3E-33mmHg at 25°C
|
| LogP |
-2.5
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
440
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=C(C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)C(=O)N
|
| InChi Key |
OBZJZDHRXBKKTJ-JTFADIMSSA-N
|
| InChi Code |
InChI=1S/C12H15N5O5/c13-9-6-4(10(14)21)1-17(11(6)16-3-15-9)12-8(20)7(19)5(2-18)22-12/h1,3,5,7-8,12,18-20H,2H2,(H2,14,21)(H2,13,15,16)/t5-,7-,8-,12-/m1/s1
|
| Chemical Name |
4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxamide
|
| Synonyms |
B-90912 B 90912 Sangivamycin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~323.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2333 mL | 16.1666 mL | 32.3332 mL | |
| 5 mM | 0.6467 mL | 3.2333 mL | 6.4666 mL | |
| 10 mM | 0.3233 mL | 1.6167 mL | 3.2333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
